You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
McKinsey
Mallinckrodt
McKesson
Dow

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for F901318

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for F901318?

F901318 is an investigational drug.

There have been 17 clinical trials for F901318. The most recent clinical trial was a Phase 1 trial, which was initiated on June 6th 2018.

The most common disease conditions in clinical trials are Aspergillosis, Leukemia, Myeloid, Acute, and Mycoses. The leading clinical trial sponsors are F2G Ltd., Hammersmith Medicines Research, and Quotient Clinical.

There are two US patents protecting this investigational drug and twenty-five international patents.

Recent Clinical Trials for F901318
TitleSponsorPhase
A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of OlorofimCovancePhase 1
A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of OlorofimF2G Ltd.Phase 1
Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon OlorofimHammersmith Medicines ResearchPhase 1

See all F901318 clinical trials

Clinical Trial Summary for F901318

Top disease conditions for F901318
Top clinical trial sponsors for F901318

See all F901318 clinical trials

International Patents for F901318

Drugname Country Document Number Estimated Expiration Related US Patent
F901318 Australia 2015348043 2034-11-21   Start Trial
F901318 Brazil 112017010439 2034-11-21   Start Trial
F901318 Canada 2982660 2034-11-21   Start Trial
F901318 China 107207470 2034-11-21   Start Trial
F901318 Cyprus 1120907 2034-11-21   Start Trial
F901318 Denmark 3221308 2034-11-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
McKinsey
Mallinckrodt
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.